Literature DB >> 1673720

Restriction fragment length polymorphism analysis of HLA-DR, DQ, DP and C4 alleles in Caucasians with systemic lupus erythematosus.

J D Reveille1, K L Anderson, R E Schrohenloher, R T Acton, B O Barger.   

Abstract

HLA-DR, DQ, DP and C4 null alleles were determined by restriction fragment length polymorphism (RFLP) analysis in 60 Caucasian patients with systemic lupus erythematosus (SLE) and 66 controls. DR3 (DRw17) and DQw2.1 were increased in frequency in the patients with SLE associated with the presence of C4A null genes. HLA-DP alleles determined by RFLP analysis of genomic DNA as well as of PCR amplified DNA were not associated with SLE or any clinical or autoantibody subset thereof. No DR, DQ, or C4 null gene association was found with renal or neuropsychiatric involvement or nDNA antibodies (or levels thereof). These data suggest that the primary predisposition to SLE lies with HLA-DR or C4 null alleles, and not with HLA-DP.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673720

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  9 in total

Review 1.  Frequency and genetic background of the position 122 (Val----Ile) variant transthyretin gene in the black population.

Authors:  D R Jacobson; J D Reveille; J N Buxbaum
Journal:  Am J Hum Genet       Date:  1991-07       Impact factor: 11.025

2.  Association of polar amino acids at position 26 of the HLA-DQB1 first domain with the anticentromere autoantibody response in systemic sclerosis (scleroderma).

Authors:  J D Reveille; D Owerbach; R Goldstein; R Moreda; R A Isern; F C Arnett
Journal:  J Clin Invest       Date:  1992-04       Impact factor: 14.808

3.  Antigen nonspecific effect of major histocompatibility complex haplotype on autoantibody levels in systemic lupus erythematosus-prone lpr mice.

Authors:  P L Cohen; E Creech; D Nakul-Aquaronne; R McDaniel; S Ackler; R G Rapoport; E S Sobel; R A Eisenberg
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

4.  HLA-DP does not contribute towards susceptibility to systemic lupus erythematosus.

Authors:  E J Davies; C J Hutchings; M C Hillarby; R P Donn; R G Cooper; E M Hay; R M Bernstein; P J Holt; D M Grennan; W E Ollier
Journal:  Ann Rheum Dis       Date:  1994-03       Impact factor: 19.103

5.  Association of amino acid sequences in the HLA-DQB1 first domain with antitopoisomerase I autoantibody response in scleroderma (progressive systemic sclerosis).

Authors:  J D Reveille; E Durban; M J MacLeod-St Clair; R Goldstein; R Moreda; R D Altman; F C Arnett
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

6.  Clinical, immunological, and immunogenetic aspects of autoantibody production against Ro/SSA, La/SSB and their linear epitopes in primary Sjögren's syndrome (pSS): a European multicentre study.

Authors:  A G Tzioufas; R Wassmuth; U G Dafni; A Guialis; H-J Haga; D A Isenberg; R Jonsson; J R Kalden; H Kiener; C Sakarellos; J S Smolen; N Sutcliffe; C Vitali; E Yiannaki; H M Moutsopoulos
Journal:  Ann Rheum Dis       Date:  2002-05       Impact factor: 19.103

7.  Identification of a significant association of a single nucleotide polymorphism in TNXB with systemic lupus erythematosus in a Japanese population.

Authors:  Yoichiro Kamatani; Koichi Matsuda; Tetsuya Ohishi; Shigeru Ohtsubo; Keiko Yamazaki; Aritoshi Iida; Naoya Hosono; Michiaki Kubo; Wako Yumura; Kosaku Nitta; Toyomasa Katagiri; Yasushi Kawaguchi; Naoyuki Kamatani; Yusuke Nakamura
Journal:  J Hum Genet       Date:  2007-12-06       Impact factor: 3.172

8.  HLA antigens in Malay patients with systemic lupus erythematosus: association with clinical and autoantibody expression.

Authors:  M R Azizah; S S Ainol; N C Kong; Y Normaznah; M N Rahim
Journal:  Korean J Intern Med       Date:  2001-06       Impact factor: 2.884

9.  The involvement of HLA -DRB1*, DQA1*, DQB1* and complement C4A loci in diagnosing systemic lupus erythematosus among Tunisians.

Authors:  Khaled Ayed; Yousr Gorgi; Saloua Ayed-Jendoubi; Rafika Bardi
Journal:  Ann Saudi Med       Date:  2004 Jan-Feb       Impact factor: 1.526

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.